CR20130169A - Monohidrato de derivados de aza-adamantano - Google Patents
Monohidrato de derivados de aza-adamantanoInfo
- Publication number
- CR20130169A CR20130169A CR20130169A CR20130169A CR20130169A CR 20130169 A CR20130169 A CR 20130169A CR 20130169 A CR20130169 A CR 20130169A CR 20130169 A CR20130169 A CR 20130169A CR 20130169 A CR20130169 A CR 20130169A
- Authority
- CR
- Costa Rica
- Prior art keywords
- monohidrate
- aza
- adamantan
- derivatives
- adamantan derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Abstract
Forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, composiciones que comprenden dicho compuesto y un proceso para preparar el compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38567410P | 2010-09-23 | 2010-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130169A true CR20130169A (es) | 2013-06-12 |
Family
ID=44736085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130169A CR20130169A (es) | 2010-09-23 | 2013-04-15 | Monohidrato de derivados de aza-adamantano |
CR20130594A CR20130594A (es) | 2010-09-23 | 2013-11-14 | Monohidrato de derivados de aza-adamantano |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130594A CR20130594A (es) | 2010-09-23 | 2013-11-14 | Monohidrato de derivados de aza-adamantano |
Country Status (24)
Country | Link |
---|---|
US (2) | US9464078B2 (es) |
EP (1) | EP2619205B1 (es) |
JP (2) | JP2013537912A (es) |
KR (1) | KR20130108586A (es) |
CN (2) | CN103180321A (es) |
AR (1) | AR083100A1 (es) |
AU (1) | AU2011305462B2 (es) |
BR (2) | BR112013005434A2 (es) |
CA (1) | CA2809675A1 (es) |
CL (2) | CL2013000756A1 (es) |
CO (1) | CO6720965A2 (es) |
CR (2) | CR20130169A (es) |
DO (2) | DOP2013000064A (es) |
EC (1) | ECSP13012575A (es) |
GT (1) | GT201300064A (es) |
MX (1) | MX2013003344A (es) |
NZ (2) | NZ609761A (es) |
PE (1) | PE20131394A1 (es) |
RU (2) | RU2016105706A (es) |
SG (2) | SG2014013460A (es) |
TW (2) | TW201212914A (es) |
UA (1) | UA110802C2 (es) |
UY (1) | UY33628A (es) |
WO (1) | WO2012040404A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
KR20130108586A (ko) | 2010-09-23 | 2013-10-04 | 애브비 인코포레이티드 | 아자아다만탄 유도체의 일수화물 |
US8802693B1 (en) | 2011-03-09 | 2014-08-12 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
US20130317055A1 (en) * | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
WO2014164682A1 (en) | 2013-03-12 | 2014-10-09 | Abbvie Inc. | Azaadamantane formate ester and process preparing azaadamantane derivatives |
AR098747A1 (es) * | 2013-12-13 | 2016-06-08 | Allergan Inc | Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso |
EP3233087B1 (en) | 2014-12-16 | 2019-10-02 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
AU2016274694A1 (en) | 2015-06-10 | 2018-01-18 | Axovant Sciences Gmbh | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors |
JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2514006A1 (fr) | 1981-10-05 | 1983-04-08 | Nativelle Sa Ets | Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique |
EP0088484A1 (en) | 1982-02-04 | 1983-09-14 | Fbc Limited | Herbicidal thiadiazolyl N-aminoureas |
GB8523211D0 (en) | 1985-09-19 | 1985-10-23 | Beecham Group Plc | Compounds |
EP0350130A3 (en) | 1988-07-07 | 1991-07-10 | Duphar International Research B.V | New substituted 1,7-annelated 1h-indazoles |
US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
US5434151A (en) | 1992-08-24 | 1995-07-18 | Cytomed, Inc. | Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase |
US5840903A (en) | 1992-07-27 | 1998-11-24 | G. D. Searle & Co. | 4-aminomethyl-1-azaadamantane derived benzamides |
JP3235913B2 (ja) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
US5821370A (en) | 1994-10-24 | 1998-10-13 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
US5852037A (en) | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
AU1128297A (en) | 1995-12-06 | 1997-06-27 | Eli Lilly And Company | Composition for treating pain |
WO1998027983A1 (en) | 1996-12-20 | 1998-07-02 | Novo Nordisk A/S | A method of treating hypercholesterolemia and related disorders |
US7732163B2 (en) | 1997-08-21 | 2010-06-08 | Board Of Trustees Of The University Of Arkansas | Extracellular serine protease |
US8236500B2 (en) | 1997-10-23 | 2012-08-07 | The United States Of America, As Represented By The Department Of Veterans Affairs | Promoter variants of the alpha-7 nicotinic acetylcholine receptor |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
ATE213246T1 (de) | 1997-11-12 | 2002-02-15 | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren | |
US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
US6057446A (en) | 1998-04-02 | 2000-05-02 | Crooks; Peter Anthony | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds |
ES2199561T3 (es) | 1998-04-02 | 2004-02-16 | Targacept, Inc. | Derivados de azatriciclo(3.3.1.1)decano y composiciones farmaceuticas que los contienen. |
US5986100A (en) | 1998-04-02 | 1999-11-16 | Crooks; Peter Anthony | Pharmaceutical compositions and methods for use |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
WO1999062505A2 (en) | 1998-06-01 | 1999-12-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
US6093724A (en) * | 1998-08-18 | 2000-07-25 | Ucb, S.A. | Muscarinic agonists and antagonists |
ATE261448T1 (de) | 1999-05-04 | 2004-03-15 | Neurosearch As | Heteroaryl diazabicycloalkene, deren herstellung und verwendung |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
BR0011534A (pt) | 1999-05-24 | 2002-02-26 | Targacept Inc | Alquilaminas aril substituìdas capazes de ativação de receptores colinérgicos nicotìnicos |
WO2001040261A1 (en) | 1999-12-01 | 2001-06-07 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
AU2001257449A1 (en) | 2000-05-01 | 2001-11-12 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
AU2001265831B9 (en) | 2000-07-04 | 2006-08-31 | Neurosearch A/S | Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
US7112593B2 (en) | 2001-03-27 | 2006-09-26 | Eisai Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
US20030119060A1 (en) * | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
FR2832713B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
CA2470567A1 (en) | 2001-12-14 | 2003-06-26 | Targacept, Inc. | Methods and compositions for treatment of central nervous system disorders |
US7300933B2 (en) | 2002-05-07 | 2007-11-27 | Neurosearch A/S | Diazabicyclic biaryl derivatives |
US7049374B2 (en) | 2002-07-18 | 2006-05-23 | Chevron U.S.A. Inc. | Heterodiamondoids |
MXPA05001702A (es) | 2002-08-14 | 2005-04-19 | Neurosearch As | Derivados de quinuclidina novedosos y su uso. |
US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
WO2004091646A2 (en) | 2003-04-16 | 2004-10-28 | Applied Research Systems Ars Holding, N.V. | Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス, インコーポレイテッド | c−Kit調節因子および使用方法 |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
WO2006065233A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
JP2005232071A (ja) | 2004-02-19 | 2005-09-02 | Kanto Chem Co Inc | ピラゾール誘導体 |
MXPA06012595A (es) | 2004-04-29 | 2007-05-09 | Abbott Lab | Analogos de amino-tetrazoles y metodos de uso. |
EA014419B1 (ru) | 2004-05-24 | 2010-12-30 | Эмджен Инк. | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения |
AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
FR2872165B1 (fr) | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | Nouveaux derives de pyrimido-benzimidazole |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CN101087756B (zh) | 2004-07-23 | 2011-04-06 | 纽阿达有限责任公司 | 肽酶抑制剂 |
EP2404605B1 (en) | 2004-08-25 | 2015-04-22 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
EP1802616B1 (en) | 2004-10-15 | 2011-01-12 | NeuroSearch A/S | Novel azabicyclic aryl derivatives and their medical use |
WO2006045716A1 (en) | 2004-10-20 | 2006-05-04 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
WO2007024391A2 (en) | 2005-07-22 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US7897766B2 (en) | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
NZ567048A (en) | 2005-12-06 | 2010-12-24 | Neurosearch As | Novel diazabicyclic aryl derivatives and their medical use |
US20090291976A1 (en) | 2006-06-27 | 2009-11-26 | Peter Andrew Ferchmin | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors |
FR2905009A1 (fr) | 2006-08-18 | 2008-02-22 | Servier Lab | Methode de criblage de composes aux proprietes anti-amyloide |
US20100234349A1 (en) | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
KR20090087009A (ko) | 2006-10-27 | 2009-08-14 | 메디베이션 뉴롤로지 인코퍼레이티드 | 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법 |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
CN101541792A (zh) * | 2006-11-06 | 2009-09-23 | 艾博特公司 | 氮杂金刚烷衍生物和应用方法 |
RU2441868C2 (ru) | 2007-02-09 | 2012-02-10 | Астеллас Фарма Инк. | Аза-кольцевое соединение с внутренним мостиком |
WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
WO2008112177A2 (en) | 2007-03-08 | 2008-09-18 | Genizon Biosciences, Inc. | Genemap of the human genes associated with schizophrenia |
MX2009010174A (es) | 2007-03-23 | 2009-10-12 | Abbott Lab | Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos. |
ES2521494T3 (es) | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
US8697722B2 (en) | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
WO2009058120A1 (en) | 2007-11-02 | 2009-05-07 | Sri International | Nicotinic acetylcholine receptor modulators |
US8273889B2 (en) | 2007-11-20 | 2012-09-25 | Nissan Chemical Industries, Ltd. | Method for producing 2-azaadamantane |
DE102007058504A1 (de) | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR) |
EP2254598B1 (en) | 2008-02-13 | 2013-07-10 | Targacept, Inc. | Combination of alpha 7 nicotinic agonists and antipsychotics |
US20090239901A1 (en) | 2008-03-19 | 2009-09-24 | Merouane Bencherif | Method and compositions for treatment of cerebral malaria |
US20110098312A1 (en) | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
FR2931677B1 (fr) | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
CA2727141A1 (en) | 2008-06-13 | 2009-12-17 | Centre For Addiction And Mental Health | Compositions and methods for modulating nicotinic/nmda receptor function |
WO2010030887A1 (en) | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
US8435762B2 (en) | 2008-10-09 | 2013-05-07 | Howard Hughes Medical Institute | Chimeric ligand-gated ion channels and methods of use thereof |
WO2010056622A1 (en) | 2008-11-11 | 2010-05-20 | Targacept, Inc. | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS |
WO2010088400A1 (en) | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
AU2010278730A1 (en) | 2009-07-31 | 2012-03-01 | Biocryst Pharmaceuticals, Inc. | Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors |
EP2467131A4 (en) | 2009-08-21 | 2014-02-19 | Univ Florida | FORMULATIONS OF ANABASEIN COMPOUNDS WITH TAXED RELEASE AND THEIR USE |
WO2011044537A2 (en) | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | Methods for treating alzheimer's disease |
WO2011058582A1 (en) | 2009-11-16 | 2011-05-19 | Orchid Research Laboratories Ltd. | Histone deacetylase inhibitors for the treatment of fungal infections |
KR20130108586A (ko) | 2010-09-23 | 2013-10-04 | 애브비 인코포레이티드 | 아자아다만탄 유도체의 일수화물 |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
-
2011
- 2011-09-21 KR KR1020137010192A patent/KR20130108586A/ko not_active Application Discontinuation
- 2011-09-21 SG SG2014013460A patent/SG2014013460A/en unknown
- 2011-09-21 US US13/238,239 patent/US9464078B2/en not_active Expired - Fee Related
- 2011-09-21 CN CN2011800458669A patent/CN103180321A/zh active Pending
- 2011-09-21 WO PCT/US2011/052668 patent/WO2012040404A1/en active Application Filing
- 2011-09-21 UA UAA201305205A patent/UA110802C2/uk unknown
- 2011-09-21 BR BR112013005434A patent/BR112013005434A2/pt not_active IP Right Cessation
- 2011-09-21 NZ NZ609761A patent/NZ609761A/en not_active IP Right Cessation
- 2011-09-21 NZ NZ707955A patent/NZ707955A/en not_active IP Right Cessation
- 2011-09-21 PE PE2013000540A patent/PE20131394A1/es not_active Application Discontinuation
- 2011-09-21 RU RU2016105706A patent/RU2016105706A/ru not_active Application Discontinuation
- 2011-09-21 AU AU2011305462A patent/AU2011305462B2/en not_active Ceased
- 2011-09-21 SG SG2013014329A patent/SG188307A1/en unknown
- 2011-09-21 RU RU2013118560/04A patent/RU2579121C2/ru not_active IP Right Cessation
- 2011-09-21 EP EP11764428.6A patent/EP2619205B1/en active Active
- 2011-09-21 CN CN201610412845.0A patent/CN106074548A/zh active Pending
- 2011-09-21 MX MX2013003344A patent/MX2013003344A/es unknown
- 2011-09-21 JP JP2013530292A patent/JP2013537912A/ja active Pending
- 2011-09-21 BR BR122014023207-1A patent/BR122014023207A2/pt not_active IP Right Cessation
- 2011-09-21 CA CA2809675A patent/CA2809675A1/en not_active Abandoned
- 2011-09-23 AR ARP110103496A patent/AR083100A1/es unknown
- 2011-09-23 TW TW100134437A patent/TW201212914A/zh unknown
- 2011-09-23 UY UY0001033628A patent/UY33628A/es unknown
- 2011-09-23 TW TW105100070A patent/TW201626996A/zh unknown
-
2013
- 2013-03-12 GT GT201300064A patent/GT201300064A/es unknown
- 2013-03-20 CL CL2013000756A patent/CL2013000756A1/es unknown
- 2013-03-22 DO DO2013000064A patent/DOP2013000064A/es unknown
- 2013-04-15 CR CR20130169A patent/CR20130169A/es unknown
- 2013-04-17 CO CO13098843A patent/CO6720965A2/es not_active Application Discontinuation
- 2013-04-23 EC ECSP13012575 patent/ECSP13012575A/es unknown
- 2013-07-17 DO DO2013000249A patent/DOP2013000249A/es unknown
- 2013-11-14 CR CR20130594A patent/CR20130594A/es unknown
-
2014
- 2014-03-18 CL CL2014000651A patent/CL2014000651A1/es unknown
-
2015
- 2015-05-08 US US14/707,681 patent/US20150239882A1/en not_active Abandoned
-
2016
- 2016-10-21 JP JP2016206552A patent/JP2017039764A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130594A (es) | Monohidrato de derivados de aza-adamantano | |
PH12016501375A1 (en) | Pyridin-2-amides useful as cb2 agonists | |
CR20120277A (es) | Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa | |
BR112012033278A2 (pt) | composições de éster de celulose/elastômero, artigo, e, processo para produzir uma composição de éster de celulose/elastômero | |
MX2010012298A (es) | Activadores de glucocinasa. | |
MY150542A (en) | Cmet inhibitors | |
MX2014005803A (es) | Composiciones de ester de celulosa/elastomero. | |
CL2012000311A1 (es) | Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales. | |
CL2012003491A1 (es) | Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva. | |
CL2013001221A1 (es) | Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto. | |
CR20140546A (es) | Forma cristalina a de 1,5-dimetil-6-tioxo-3- (2,2,7-trifluoro- 3-oxo-4- (prop-2-inil)-3,4-dihidro -2h-benzo [b] [1,4] oxazin-6-il)-1,3,5- triazinan-2,4-diona | |
MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
EA201890075A1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
CL2011003123A1 (es) | Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras. | |
GB201020397D0 (en) | Compounds | |
MX2015016766A (es) | Nuevos derivados de tetrazolona. | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
CO7200259A2 (es) | Nuevos derivados de piridina | |
TW201612188A (en) | The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor | |
CL2012000350A1 (es) | Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl. | |
MX2013007504A (es) | Composiciones y metodos de uso de formas cristalinas de analogos de wortmanina. | |
CY1116535T1 (el) | Μεθοδος συνθεσης παραγωγων της 7,8-διμεθοξυ-1,3-διυδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη στην συνθεση της ιβαμπραδινης | |
EA201400882A1 (ru) | Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях | |
RU2009142542A (ru) | Пиролизный реактор |